Results 181 to 190 of about 103,961 (275)

Safety and effectiveness of nivolumab in patients with locally advanced or metastatic non-small cell lung cancer in China: a nationwide electronic health record dataset analysis. [PDF]

J Thorac Dis
Fu X, Liang Y, Xu Y, Wang Q, Li A, Yao Y.   +5 more
europepmc   +1 more source

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

Journal of Cutaneous Pathology, EarlyView.
Annie Jin, Katherine T. Steele, Emily Y. Chu   +2 more
wiley   +1 more source

National survey of real‐world treatment patterns for early‐ and intermediate‐stage hepatocellular carcinoma reveals wide variation across Australian states

Internal Medicine Journal, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is a heterogeneous and multi‐disease state that is complex to manage and requires a multidisciplinary approach to optimise patient care. Best practice recommendations were proposed in the Australian HCC consensus statement published in 2020.
Stuart K. Roberts, Ammar Majeed, Kiran Rasaratnam, John K. Olynyk, Nicholas Shackel, Marnie Wood, Alan Wigg, Simone I. Strasser   +7 more
wiley   +1 more source

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. [PDF]

Nat Commun
Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, Goekkurt E, Dechow TN, Ettrich TJ, Hofheinz RD, Luley KB, Pink D, Lindig U, Folprecht G, Schuch G, Bitzer M, Heinemann V, Angermeier S, Bolling C, Loose M, Junge S, Pauligk C, Al-Batran SE.   +20 more
europepmc   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report. [PDF]

IJU Case Rep
Shimoda H, Fukuda S, Yafuso D, Yamamoto K, Ishikawa Y, Fukushima H, Waseda Y, Tanaka H, Yoshida S, Fujii Y.   +9 more
europepmc   +1 more source

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

Journal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu, Agata Kurowski, Malini P. Naidu, Jonas Adalsteinsson, Shane A. Meehan, Natalia Alkon, Lauren R. Port, Sumanth Chennareddy, Emry R. Cohenour, Grace Christensen, Jonah Shulman, Nicholas Gulati, Constanze Jonak, Patrick M. Brunner   +13 more
wiley   +1 more source

Readministration of nivolumab for patients with advanced gastric cancer: a case series. [PDF]

ESMO Gastrointest Oncol
Kodama H, Narita Y, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ando M, Tajika M, Yamaguchi T, Nishikawa H, Muro K.   +10 more
europepmc   +1 more source

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. [PDF]

, 2020
Chae, Young Kwang, Kurzrock, Razelle, Othus, Megan, Patel, Sandip P, S1609 Team   +4 more
core